Please login to the form below

Not currently logged in
Email:
Password:

Ardelyx appoints William Bertrand Jr to board of directors

Executive VP of Infinity Pharmaceuticals joins the team
Ardelyx

Ardelyx has appointed William Bertrand Jr to its board of directors.

Ardelyx is a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases.

Bertrand is currently executive VP of general counsel for Infinity Pharmaceuticals and prior to this he served as senior VP and CEO for Salix Pharmaceuticals.

He said: “Ardelyx is uniquely positioned within the life sciences, both in terms of the strength and track record of its senior team, as well as its strategy addressing diseases with substantial unmet needs.”

Mike Raab, president and CEO of Ardelyx, added: “Bill brings extensive experience helping companies growth through early stages of development and into commercialisation.

“His expertise, both operationally and as general counsel, will be of great importance as we continue to accelerate the advancement of our lead programs and develop into a commercial-ready company.”

27th October 2015

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics